Gillian McGovern is an associate editor at Pharmacy Times®. She graduated from Rowan University in 2023 with a BA in Writing Arts and concentrations in Publishing & Writing for the Public, Technical & Professional Writing, and Creative Writing.
FDA Grants Fast Track Designation for AC699 for Patients With ER+/HER2– Breast Cancer
August 15th 2024AC699 is being evaluated for patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 negative (HER2–), estrogen receptor 1-mutated advanced or metastatic breast cancer with disease progression on or after at least 1 line of endocrine-based therapy.
Read More
FDA Approves Vorasidenib for Adults, Pediatric Patients With Grade 2 Astrocytoma, Oligodendroglioma
August 7th 2024This marks the first FDA-approved systemic therapy for patients with grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IHD1) or IDH2 mutation.
Read More
Expert: The Definition of Alzheimer Disease is Shifting From Clinical to Biological
August 2nd 2024Edward B. Lee, MD, PhD, also describes how understanding Alzheimer disease requires the integration of multiple fields including genetics, pathology, epidemiology, pharmacology, and physiology.
Read More